Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy

Abstract

Background: The clinical features of patients with small cell lung cancer (SCLC) and idiopathic pulmonary fibrosis (IPF) have not been fully elucidated. Patients and methods: Data on 366 patients with pathologically confirmed SCLC who had been treated with chemotherapy or chemoradiotherapy were retrospectively analyzed to investigate the clinical features of SCLC with IPF. Results: A total of 97 out of the 366 patients were diagnosed with interstitial lung disease (ILD), and 75 of them had IPF. For both the limited disease (LD) and extensive disease (ED) stages, the median progression-free survival (PFS) and overall survival (OS) were significantly shorter in the patients with IPF compared with non-ILD patients. A multivariate analysis showed that poor performance status, ED stage, and the presence of IPF were associated with shorter OS. The response rate to first-line therapy was significantly lower in patients with IPF compared with the non-ILD patients. The rate of patients receiving fewer than three cycles of first-line chemotherapy was higher in patients with IPF, which was a factor of poor survival. In LD-stage patients with IPF, chemoradiotherapy was associated with longer PFS and OS compared with chemotherapy only. Conclusion: In patients with SCLC, the presence of IPF was associated with a lower response rate as well as shorter PFS and shorter OS. There are some cases that are suitable for chemoradiotherapy, even among patients with IPF. The reviews of this paper are available via the supplemental material section.

Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis

“…The main characteristics of all 12 studies that met our inclusion and exclusion criteria were displayed in Table 1 [34][35][36][37][38][39][40][41][42][43][44][45].…”

“…Of all included studies, 10 were conducted in Asia [35-42, 44, 45] and the rest were in the United States of America (USA) [34,43]. All 12 studies were retrospective, consist of 1 casecontrol study [39] and 11 cohort studies [34][35][36][37][38][40][41][42][43][44][45]. The sample size ranged from 86 to 54453.…”

“…The sample size ranged from 86 to 54453. Of all studies, 10 enrolled patients with NSCLC [34-38, 40, 41, 43, 45] while 2 enrolled SCLC patients [42,44]. Patients of 7 studies received surgery [34][35][36][37][38][39]45] while 4 studies received chemotherapy, radiotherapy, or target therapy [40][41][42]44].…”

“…Of all studies, 10 enrolled patients with NSCLC [34-38, 40, 41, 43, 45] while 2 enrolled SCLC patients [42,44]. Patients of 7 studies received surgery [34][35][36][37][38][39]45] while 4 studies received chemotherapy, radiotherapy, or target therapy [40][41][42]44]. All studies defined OS as the time from diagnosis to the day of death or last follow-up.…”

Diagnostic Value of Serum Levels of IL-22, IL-23, and IL-17 for Idiopathic Pulmonary Fibrosis Associated with Lung Cancer

“… 7–9 It has been estimated that the incidence rate of lung cancer associated IPF patients ranges from about 10% to 40%. Unfortunately, lung cancer has also become a major contributor to IPF related-death among the above patients 10–12 and the prognosis for patients with IPF associated lung cancer remains poor.…”